The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

10.1186/1471-2474-15-178

Saved in:

Bibliographic Details
Main Authors:	Marco, H, Smith, R.M, Jones, R.B, Guerry, M.-J, Catapano, F, Burns, S, Chaudhry, A.N, Smith, K.G, Jayne, D.R
Other Authors:	MEDICINE
Format:	Article
Published:	2020
Subjects:	alemtuzumab antineoplastic agent azathioprine cyclophosphamide glucocorticoid hydroxychloroquine immunoglobulin immunoglobulin A immunoglobulin G immunoglobulin M methotrexate methylprednisolone mycophenolic acid 2 morpholinoethyl ester prednisolone rituximab immunologic factor monoclonal antibody adolescent adult aged anaphylactoid purpura article autoimmune disease Behcet disease Churg Strauss syndrome controlled study disease activity disease duration drug effect female follow up human immunoglobulin blood level immunoglobulin deficiency immunotherapy infection rate maintenance therapy major clinical study male microscopic polyangiitis multisystem autoimmune disease randomized controlled trial (topic) retrospective study systemic lupus erythematosus systemic vasculitis treatment duration treatment response Wegener granulomatosis agammaglobulinemia Autoimmune Diseases blood chemically induced middle aged treatment outcome very elderly young adult Adolescent Adult Agammaglobulinemia Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Female Follow-Up Studies Humans Immunoglobulins Immunologic Factors Male Middle Aged Retrospective Studies Treatment Outcome Young Adult
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181500
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181500
record_format	dspace
spelling	sg-nus-scholar.10635-1815002024-11-13T18:29:32Z The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease Marco, H Smith, R.M Jones, R.B Guerry, M.-J Catapano, F Burns, S Chaudhry, A.N Smith, K.G Jayne, D.R MEDICINE alemtuzumab antineoplastic agent azathioprine cyclophosphamide glucocorticoid hydroxychloroquine immunoglobulin immunoglobulin A immunoglobulin G immunoglobulin M methotrexate methylprednisolone mycophenolic acid 2 morpholinoethyl ester prednisolone rituximab immunoglobulin immunologic factor monoclonal antibody rituximab adolescent adult aged anaphylactoid purpura article autoimmune disease Behcet disease Churg Strauss syndrome controlled study disease activity disease duration drug effect female follow up human immunoglobulin blood level immunoglobulin deficiency immunotherapy infection rate maintenance therapy major clinical study male microscopic polyangiitis multisystem autoimmune disease randomized controlled trial (topic) retrospective study systemic lupus erythematosus systemic vasculitis treatment duration treatment response Wegener granulomatosis agammaglobulinemia Autoimmune Diseases blood chemically induced middle aged treatment outcome very elderly young adult Adolescent Adult Agammaglobulinemia Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Autoimmune Diseases Female Follow-Up Studies Humans Immunoglobulins Immunologic Factors Male Middle Aged Retrospective Studies Treatment Outcome Young Adult 10.1186/1471-2474-15-178 BMC Musculoskeletal Disorders 15 1 178 2020-10-27T11:07:25Z 2020-10-27T11:07:25Z 2014 Article Marco, H, Smith, R.M, Jones, R.B, Guerry, M.-J, Catapano, F, Burns, S, Chaudhry, A.N, Smith, K.G, Jayne, D.R (2014). The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskeletal Disorders 15 (1) : 178. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2474-15-178 14712474 https://scholarbank.nus.edu.sg/handle/10635/181500 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	alemtuzumab antineoplastic agent azathioprine cyclophosphamide glucocorticoid hydroxychloroquine immunoglobulin immunoglobulin A immunoglobulin G immunoglobulin M methotrexate methylprednisolone mycophenolic acid 2 morpholinoethyl ester prednisolone rituximab immunoglobulin immunologic factor monoclonal antibody rituximab adolescent adult aged anaphylactoid purpura article autoimmune disease Behcet disease Churg Strauss syndrome controlled study disease activity disease duration drug effect female follow up human immunoglobulin blood level immunoglobulin deficiency immunotherapy infection rate maintenance therapy major clinical study male microscopic polyangiitis multisystem autoimmune disease randomized controlled trial (topic) retrospective study systemic lupus erythematosus systemic vasculitis treatment duration treatment response Wegener granulomatosis agammaglobulinemia Autoimmune Diseases blood chemically induced middle aged treatment outcome very elderly young adult Adolescent Adult Agammaglobulinemia Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Autoimmune Diseases Female Follow-Up Studies Humans Immunoglobulins Immunologic Factors Male Middle Aged Retrospective Studies Treatment Outcome Young Adult
spellingShingle	alemtuzumab antineoplastic agent azathioprine cyclophosphamide glucocorticoid hydroxychloroquine immunoglobulin immunoglobulin A immunoglobulin G immunoglobulin M methotrexate methylprednisolone mycophenolic acid 2 morpholinoethyl ester prednisolone rituximab immunoglobulin immunologic factor monoclonal antibody rituximab adolescent adult aged anaphylactoid purpura article autoimmune disease Behcet disease Churg Strauss syndrome controlled study disease activity disease duration drug effect female follow up human immunoglobulin blood level immunoglobulin deficiency immunotherapy infection rate maintenance therapy major clinical study male microscopic polyangiitis multisystem autoimmune disease randomized controlled trial (topic) retrospective study systemic lupus erythematosus systemic vasculitis treatment duration treatment response Wegener granulomatosis agammaglobulinemia Autoimmune Diseases blood chemically induced middle aged treatment outcome very elderly young adult Adolescent Adult Agammaglobulinemia Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Autoimmune Diseases Female Follow-Up Studies Humans Immunoglobulins Immunologic Factors Male Middle Aged Retrospective Studies Treatment Outcome Young Adult Marco, H Smith, R.M Jones, R.B Guerry, M.-J Catapano, F Burns, S Chaudhry, A.N Smith, K.G Jayne, D.R The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
description	10.1186/1471-2474-15-178
author2	MEDICINE
author_facet	MEDICINE Marco, H Smith, R.M Jones, R.B Guerry, M.-J Catapano, F Burns, S Chaudhry, A.N Smith, K.G Jayne, D.R
format	Article
author	Marco, H Smith, R.M Jones, R.B Guerry, M.-J Catapano, F Burns, S Chaudhry, A.N Smith, K.G Jayne, D.R
author_sort	Marco, H
title	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
title_short	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
title_full	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
title_fullStr	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
title_full_unstemmed	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
title_sort	effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181500
_version_	1821203111652360192

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

Similar Items